Lifeboat Foundation

For cancer research, meanwhile, the situation is more akin to an economic revolution, or disruptive advance in technology. Because all cancers must lengthen their telomeres, and because telomere lengthening is governed by a small number of processes, there is the opportunity to change the focus of cancer research from an endless procession of expensive new therapies, each targeting a tiny number of the hundreds of subtypes of cancer, to one single therapy that can effectively suppress all cancers.

The last few days have arrived for this year’s SENS Research Foundation crowdfunding campaign, focused on important groundwork to establish a universal therapy for all types of cancer. There are still a few thousand dollars left in the matching fund, so donations are still being matched. Cancer is just as much a part of aging that must be ended, brought completely under control, as all of the other line items in the SENS rejuvenation research portfolio, and this year is the first time that the SENS Research Foundation has run a fundraiser for this program.

Hopefully there is no need to remind the audience here that the SENS Research Foundation, and important ally the Methuselah Foundation, have in recent years achieved great progress in the field of rejuvenation research on the basis of our donations and our support. Some of the high points you’ll find mentioned here and there at Fight Aging!: support and ongoing expansion of the mitochondrial repair technologies now under development at Gensight; seed funding Oisin Biotechnologies for senescent cell clearance; unblocking efforts to clear glucosepane cross-links that stiffen tissues; running the lauded Rejuvenation Biotechnology conferences; and many more. If only all charities produced as great an impact with as few resources — and if only we were further along in the bootstrapping of an industry focused on the development of rejuvenation therapies.

Continue reading “Entering the Final Days of the SENS Universal Cancer Treatment Fundraiser” »

Traditional cancer research is well funded but ALT cancers are not. SENS Research is aiming to raise funds to address this vital gap in our scientific knowledge. Most scary thing of all is that some regular cancers that abuse telomerase can switch to this ALT method to keep growing when telomerase blocking therapies are used.

The paper I’ll point out today is a timely one, given that the SENS Research Foundation’s fundraiser for early stage work on a therapy for alternative lengthening of telomeres (ALT) cancers is nearing its close. There are still thousands of dollars left in the matching fund, so give it some thought if you haven’t yet donated. The search for ways to safely sabotage ALT is a useful, important line of research because blocking telomere lengthening is a path to a universal cancer therapy, those research groups presently working on it are all looking to achieve this goal by interfering in the activities of telomerase, cancers can switch from using telomerase to using ALT, and next to no-one is working on ways to suppress ALT mechanisms. It seems fairly clear based on the evidence to date that the universal cancer therapy that lies ahead, built by inhibiting telomere lengthening, must involve a blockade of both telomerase and ALT. The open access paper below reinforces this point, the authors investigating how exactly cancers switch from telomerase to ALT to maintain their dangerous growth.

Cancer research today has a grand strategy problem. There is only so much funding and only so many researchers, but hundreds of subtypes of cancer. Therapies tend to be highly specific to the peculiarities of one type of cancer or a small class of cancers, meaning that great expense and time leads to a treatment that is only applicable for a fraction of cancer patients, all too often a tiny fraction. Further, since tumors evolve at great speed, any one individual patient’s cancer may find its way out from under the hammer by changing its signature and mode of operation. All is not doom and gloom, however. Consider that the research community could build a therapy applicable to all cancers with little to no modification, where the cost of development would be no greater than any one of the highly specific therapies presently in use and under development. That therapy would be, of course, based on the blockade of telomere lengthening.

Continue reading “An Investigation of How Telomerase Cancers can Switch to Become ALT Cancers” »

Calico, a company focused on aging research and therapeutics, today announced that Daphne Koller, Ph.D., is joining the company as Chief Computing Officer. In this newly created position, Dr. Koller will lead the company’s computational biology efforts. She will build a team focused on developing powerful computational and machine learning tools for analyzing biological and medical data sets. She and her team will work closely with the biological scientists at Calico to design experiments and construct data sets that could provide a deeper understanding into the science of longevity and support the development of new interventions to extend healthy lifespan.

Calico will try to use machine learning to understand the complex biological processes involved in aging.

Glad this discovery has been found; however, sad to hear as well. Sharing for my friends involved with anti-aging (Alex) and others work on the cancer cure.

Genetic signature of the brain cancer cell lines used for research is different from the original patient tumor cells.

I HIGHLY recommend reading this novel, as well as it sequels! It’s a beautiful, smart, and occasionally frightening exploration of what our civilization will look like post singularity, what WE will look like as posthumans, and where we might go from there.

The Golden Age is Grand Space Opera, a large-scale SF adventure novel in the tradition of A. E. Van vogt and Roger Zelazny, with perhaps a bit of Cordwainer Smith enriching the style. It is an astounding story of super science, a thrilling wonder story that recaptures the excitements of SF’s golden age writers.

The Golden Age takes place 10,000 years in the future in our solar system, an interplanetary utopian society filled with immortal humans. Within the frame of a traditional tale-the one rebel who is unhappy in utopia-Wright spins an elaborate plot web filled with suspense and passion.

Continue reading “The Golden Age” »

https://www.youtube.com/watch?v=T4U6qvNt81E&feature=youtu.be

The MMTP has recorded this film in support of SENS Research and their quest to find solutions to ALT cancer.

To support OncoSENS project with a donation click the link:

Continue reading “Elena Milova speaking in support of OncoSENS crowdfunding campaign” »

https://www.youtube.com/watch?v=5chIH_ozLkI

Inconvenient truths about aging, senescent cells and more.

Filmed August 16th 2016.

Continue reading “Aubrey de Grey and Panel — Prolonging Lifespan” »

Google’s artificial intelligence research lab DeepMind is exploring whether its technology could be used to identify early signs of eye diseases that ophthalmologists might not spot.

DeepMind, which was acquired by Google in 2014, has struck an agreement with Moorfields Eye Hospital in London that gives it access to about a million anonymous retinal scans, which it will feed into its artificial intelligence software.

Continue reading “Could an algorithm help to save people’s eyesight? Google thinks so” »

It’s an add-on for CRISPR.

Researchers have created a new genome editing technique called Target-AID, which induces point mutations instead of cutting DNA

Gene editing technology has fantastic potential, but there are remaining issues and questions over safety and specificity. The major contender is currently CRISPR-Cas9, but this induces a double stranded break in DNA which is a slightly riskier approach — particularly if it cuts in other locations too that you don’t want it to. Research teams across the world are both optimising and customising the CRISPR system; creating more accurate versions or versions that regulate gene expression as opposed to editing it. One such team has now built an add-on to CRISPR, Target-AID.

Continue reading “Safer Gene Editing Without Cleaving DNA” »